Recombinant live Salmonella spp. for human vaccination against heterologous pathogens

FEMS Immunology and Medical Microbiology

Volumn 27, Issue 4, 2000, Pages 357-364

  Bumann, D ^a   Hueck, C ^b   Aebischer, T ^a   Meyer, T F ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b CREATOGEN GmbH   (Germany)

Author keywords

Attenuated live carrier; Clinical trial; Salmonella vaccine

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIVE VACCINE; RECOMBINANT VACCINE; SALMONELLOSIS VACCINE;

ANIMAL MODEL; ANTIGEN EXPRESSION; BACTERIUM MUTANT; COST EFFECTIVENESS ANALYSIS; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; REVIEW; SALMONELLA; TYPHOID FEVER; VACCINATION;

EID: 0034056439     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(99)00214-X     Document Type: Article

References (68)

1. Chatfield, S.N. and Dougan, G. (1997) Attenuated Salmonella as a live vector for expression of foreign antigens. Part i. Expressing bacterial antigens. In: New Generation Vaccines (Levine, M.M., et al., Eds.), 2nd edn., pp. 331-341. Marcel Dekker, New York.
2. Curtiss R. III, Kelly S.M., Tinge S.A., Tacket C.O., Levine M.M., Srinivasan J., Koopman M. Recombinant Salmonella vectors in vaccine development. Dev. Biol. Stand. 82:1994;23-33.
3. Hormaeche, C.E., Khan, C.M.A., Mastroeni, P., Villarreal, B., Dougan, B., Roberts, M. and Chatfield, S.N. (1995) Salmonella vaccines: mechanisms of immunity and their use as carriers of recombinant antigens. In: Molecular and Clinical Aspects of Vaccine Development (Ala'Aldeen, D. and Hormaeche, C.E., Eds.), pp. 119-153. John Wiley, Chichester.
4. Hormaeche, C.E. and Khan, C.M.A. (1996) Recombinant bacteria as vaccine carriers of heterologous antigens. In: Concepts in Vaccine Development (Kaufmann, S.H.E., Ed.), pp. 327-349. W. de Gruyter, Berlin.
5. Levine, M.M., Tacket, C.O., Galen, J.E., Barry, E.M., Noriega, F. and Sztein, M.B. (1997) Progress in development of new attenuated strains of Salmonella typhi as live oral vaccines against typhoid fever. In: New Generation Vaccines (Levine, M.M., et al., Eds.), 2nd edn, pp. 437-446. Marcel Dekker, New York.
6. Levine, M.M., Galen, J.E., Sztein, M.B., Beier, M. and Noriega, F.R. (1997) Attenuated Salmonella as a live vector for expression of foreign antigens. Part iii. Salmonella expressing protozoal antigens. In: New Generation Vaccines (Levine, M.M., et al., Eds.), 2nd edn, pp. 351-361. Marcel Dekker, New York.
7. Roberts, M., Chatfield, S.N. and Dougan, G. (1994) Salmonella as carriers of heterologous antigens. In: Novel Delivery Systems for Oral Vaccines (O'Hagan, D.T., Ed.), pp. 27-58. CRC Press, London.
8. c expressing urease A and B subunits. Infect. Immun. 66:1998;581-586.
9. Gomez-Duarte O.G., Lucas B., Yan Z.X., Panthel K., Haas R., Meyer T.F. Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine. 16:1998;460-471.
10. Curtiss R. III, Kelly S.M. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect. Immun. 55:1987;3035-3043.
11. Hoiseth S.K., Stocker B.A.D. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature. 291:1981;238-239.
12. Kelly S.M., Bosecker B.A., Curtiss R. III. Characterization and protective properties of attenuated mutants of Salmonella choleraesuis. Infect. Immun. 60:1992;4881-4890.
13. Johnson K., Charles I., Dougan G., Pickard D., O'Gaora P., Costa G., Ali T., Miller I., Hormaeche C. The role of a stress-response protein in Salmonella typhimurium virulence. Mol. Microbiol. 5:1991;401-407.
14. Miller S.I., Kukral A.M., Mekalanos J.J. A two-component regulatory system (phoP phoQ) controls Salmonella typhimurium virulence. Proc. Natl. Acad. Sci. USA. 86:1989;5054-5058.
15. Mastroeni P., Harrison J.A., Robinson J.H., Clare S., Khan S., Maskell D.J., Dougan G., Hormaeche C.E. Interleukin-12 is required for control of the growth of attenuated aromatic-compound-dependent salmonellae in BALB/c mice: role of γ interferon and macrophage activation. Infect. Immun. 66:1998;4767-4776.
16. VanCott J.L., Chatfield S.N., Roberts M., Hone D.M., Hohmann E.L., Pascual D.W., Yamamoto M., Kiyono H., McGhee J.R. Regulation of host immune responses by modification of Salmonella virulence genes. Nat. Med. 4:1998;1247-1252.
17. Izhar M., DeSilva L., Joysey H.S., Hormaeche C.E. Moderate immunodeficiency does not increase susceptibility to Salmonella typhimurium aroA live vaccines in mice. Infect. Immun. 58:1990;2258-2261.
18. Strahan K., Chatfield S.N., Tite J., Dougan G., Hormaeche C.E. Impaired resistance to infection does not increase the virulence of Salmonella htrA live vaccines for mice. Microb. Pathog. 12:1992;311-317.
19. Medina E., Paglia P., Nikolaus T., A M., Hensel M., Guzmán C.A. Pathogenicity island 2 mutants of Salmonella typhimurium are efficient carriers for heterologous antigens and enable modulation of immune responses. Infect. Immun. 67:1999;1093-1099.
20. Vazquez-Torres, A., Xu, Y., Lucia, S., Holden, D.W. and Fang, F.C. (1999) Salmonella pathogenicity island 2-dependent evasion of the phagocyte NADPH oxidase. In: 99th General Meeting of the American Scociety for Microbiology. Chicago, IL.
21. Altare F., Lammas D., Revy P., Jouanguy E., Lamhamedi S., Drysdale P., Scheel-Toellner D., Girdlestone J., Darbyshire P., Wadhwa M., Dockrell H., Salmon M., Fischer A., Durandy A., Casanova J.L., Kumararatne D.S. Inherited interleukin 12 deficiency in a child with bacille Calmette- Guérin and Salmonella enteritidis disseminated infection. J. Clin. Invest. 102:1998;2035-2040.
22. Altare F., Durandy A., Lammas D., Emile J.-F., Lamhamedi S., Le Deist F., Drysdale P., Jouanguy E., Döffinger R., Bernaudin F., Jeppsson O., Gollob J.A., Meinl E., Segal A.W., Fischer A., Kumararatne D., Casanova J.-L. Impairment of mycobacterial immunity in human interleukin-12 receptor-deficiency. Science. 280:1998;1432-1435.
23. De Jong R., Altare F., Haagen I.-A., Elferink D.G., de Boer T., van Breda Vriesman P.J.C., Kabel P.J., Draaisma J.M.T., van Dissel J.T., Kroon F.P., Casanova J.-L., Ottenhoff T.H.M. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science. 280:1998;1435-1438.
24. Covone M.G., Brocchi M., Palla E., Dias da Silveira W., Rappuoli R., Galeotti C.L. Levels of expression and immunogenicity of attenuated Salmonella enterica serovar typhimurium strains expressing Escherichia coli mutant heat-labile enterotoxin. Infect. Immun. 66:1998;224-231.
25. Tacket C.O., Hone D.M., Curtiss R. III, Kelly S.M., Losonsky G., Guers L., Harris A.M., Edelman R., Levine M.M. Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers. Infect. Immun. 60:1992;536-541.
26. Steger K.K., Valentine P.J., Heffron F., So M., Pauza C.D. Recombinant, attenuated Salmonella typhimurium stimulate lymphoproliferative responses to SIV capsid antigen in rhesus macaques. Vaccine. 17:1999;923-932.
27. Low K.B., Ittensohn M., Le T., Platt J., Sodi S., Amoss M., Ash O., Carmichael E., Chakraborty A., Fischer J., Lin S.L., Luo X., Miller S.I., Zheng L., King I., Pawelek J.M., Bermudes D. Lipid A mutant Salmonella with suppressed virulence and TNFa induction retain tumor-targeting in vivo. Nat. Biotechnol. 17:1999;37-41.
28. Valentine P.J., Devore B.P., Heffron F. Identification of three highly attenuated Salmonella typhimurium mutants that are more immunogenic and protective in mice than a prototypical aroA mutant. Infect. Immun. 66:1998;3378-3383.
29. Benyacoub J., Hopkins S., Potts A., Kelly S., Kraehenbuhl J.P., Curtiss R., DeGrandi P. 3rd, Nardelli-Haefliger D. The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunised mice. Infect. Immun. 67:1999;3674-3679.
30. Hohmann E.L., Oletta C.A., Killeen K.P., Miller S.I. phoP/phoQ-deleted Salmonella typhi (TY800) is a safe and immunogenic single dose typhoid fever vaccine in volunteers. J. Infect. Dis. 173:1996;1408-1414.
31. Germanier R., Fürer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 131:1975;553-558.
32. Hone D.M., Attridge S.R., Forrest B., Morona R., Daniels D., LaBrooy J.T., Bartholomeusz R.C., Shearman D.J., Hackett J. A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect. Immun. 56:1988;1326-1333.
33. Engels E.A., Falagas M.E., Lau J., Bennish M.L. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. Br. Med. J. 316:1998;110-116.
34. Gilman R.H., Hornick R.B., Woodard W.E., DuPont H.L., Snyder M.J., Levine M.M., Libonati J.P. Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J. Infect. Dis. 136:1977;717-723.
35. Black R.E., Levine M.M., Ferreccio C., Clements M.L., Lanata C., Rooney J., Germanier R. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. Vaccine. 8:1990;81-84.
36. Ferreccio C., Levine M.M., Rodriguez H., Contreras R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J. Infect. Dis. 159:1989;766-769.
37. Formal S.B., Baron L.S., Kopecko D.J., Washington O., Powell C., Life C.A. Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain. Infect. Immun. 34:1981;746-750.
38. Forrest B.D., LaBrooy J.T., Attridge S.R., Boehm G., Beyer L., Morona R., Shearman D.J., Rowley D. Immunogenicity of a candidate live oral typhoid/cholera hybrid vaccine in humans. J. Infect. Dis. 159:1989;145-146.
39. Seid R.C. Jr., Kopecko D.J., Sadoff J.C., Schneider H., Baron L.S., Formal S.B. Unusual lipopolysaccharide antigens of a Salmonella typhi oral vaccine strain expressing the Shigella sonnei form I antigen. J. Biol. Chem. 259:1984;9028-9034.
40. Tacket C.O., Forrest B., Morona R., Attridge S.R., LaBrooy J., Tall B.D., Reymann M., Rowley D., Levine M.M. Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect. Immun. 58:1990;1620-1627.
41. Black R.E., Levine M.M., Clements M.L., Losonsky G., Herrington D., Berman S., Formal S.B. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J. Infect. Dis. 155:1987;1260-1265.
42. Van De Verg L., Herrington D.A., Murphy J.R., Wasserman S.S., Formal S.B., Levine M.M. Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect. Immun. 58:1990;2002-2004.
43. Herrington D.A., Van de Verg L., Formal S.B., Hale T.L., Tall B.D., Cryz S.J., Tramont E.C., Levine M.M. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine. 8:1990;353-357.
44. Hartman A.B., Ruiz M.M., Schultz C.L. Molecular analysis of variant plasmid forms of a bivalent Salmonella typhi-Shigella sonnei vaccine strain. J. Clin. Microbiol. 29:1991;27-32.
45. Saier, M.H.J., Ramseier, T.M. and Reizer, J. (1996) Regulation of carbon utilization. In: Escherichia coli and Salmonella: Cellular and Molecular Biology (Neidhardt, F.C., et al., Eds.), 2nd edn, Vol. 1, pp. 1325-1343. ASM Press, Washington, DC.
46. Tacket C.O., Kelly S.M., Schodel F., Losonsky G., Nataro J.P., Edelman R., Levine M.M., Curtiss R. III. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the asd-balanced lethal vector system. Infect. Immun. 65:1997;3381-3385.
47. Schödel F., Kelly S.M., Peterson D.L., Milich D.R., Curtiss R. III. Hybrid hepatitis B virus core-pre-s proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination. Infect. Immun. 62:1994;1669-1676.
48. Nardelli-Haefliger D., Kraehenbuhl J.P., Curtiss R., Schödel F. III, Potts A., Kelly S., De Grandi P. Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect. Immun. 64:1996;5219-5224.
49. Hone D.M., Harris A.M., Chatfield S., Dougan G., Levine M.M. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine. 9:1991;810-816.
50. Matthews, R.G. (1996) One-carbon metabolism. In: Escherichia coli and Salmonella: Cellular and Molecular Biology (Neidhardt, F.C., et al., Eds.), 2nd edn, Vol. 1, pp. 600-611. ASM Press, Washington, DC.
51. Stocker B.A.D. Aromatic-dependent Salmonella as live vaccine presenters of foreign epitopes as inserts in flagellin. Res. Microbiol. 141:1990;787-796.
52. Tacket C.O., Sztein M.B., Losonsky G.A., Wasserman S.S., Nataro J.P., Edelman R., Pickard D., Dougan G., Chatfield S.N., Levine M.M. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun. 65:1997;452-456.
53. González C., Hone D., Noriega F.R., Tacket C.O., Davis J.R., Losonsky G., Nataro J.P., Hoffman S., Malik A., Nardin E., Sztein M.B., Heppner D.G., Fouts T.R., Isibasi A., Levine M.M. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J. Infect. Dis. 169:1994;927-931.
54. Hohmann E.L., Oletta C.A., Miller S.I. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine. 14:1996;19-24.
55. Roberts M., Li J., Bacon A., Chatfield S. Oral vaccination against tetanus: comparison of the immunogenicities of Salmonella strains expressing fragment C from the nirB and htrA promoters. Infect. Immun. 66:1998;3080-3087.
56. Galán J.E., Nakayama K., Curtiss R. III. Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene. 94:1990;29-35.
57. + expression-cloning vector: stable maintenance and high level expression of cloned genes in a Salmonella vaccine strain. Bio/Technology. 6:1988;693-697.
58. + gene: application to cholera vaccine development. Gene. 107:1991;139-144.
59. Tijhaar E.J., Zheng-Xin Y., Karlas J.A., Meyer T.F., Stukart M.J., Osterhaus A.D., Mooi F.R. Construction and evaluation of an expression vector allowing the stable expression of foreign antigens in a Salmonella typhimurium vaccine strain. Vaccine. 12:1994;1004-1011.
60. Yan Z.X., Meyer T.F. Mixed population approach for vaccination with live recombinant Salmonella strains. J. Biotechnol. 44:1996;197-201.
61. Gentschev I., Mollenkopf H., Sokolovic Z., Hess J., Kaufmann S.H., Goebel W. Development of antigen-delivery systems, based on the Escherichia coli hemolysin secretion pathway. Gene. 179:1996;133-140.
62. Rüssmann H., Shams H., Poblete F., Fu Y., Galán J.E., Donis R.O. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science. 281:1998;565-568.
63. Dunstan S.J., Ramsay A.J., Strugnell R.A. Studies of immunity and bacterial invasiveness in mice given a recombinant Salmonella vector encoding murine interleukin-6. Infect. Immun. 64:1996;2730-2736.
64. + T cell subsets. Ciba Found. Symp. 187:1994;170-175.
65. Whittle B.L., Smith R.M., Matthaei K.I., Young I.G., Verma N.K. Enhancement of the specific mucosal IgA response in vivo by interleukin-5 expressed by an attenuated strain of Salmonella serotype Dublin. J. Med. Microbiol. 46:1997;1029-1038.
66. Xu D., McSorley S.J., Tetley L., Chatfield S., Dougan G., Chan W.L., Satoskar A., David J.R., Liew F.Y. Protective effect on Leishmania major infection of migration inhibitory factor, TNF-α, and IFN-γ administered orally via attenuated Salmonella typhimurium. J. Immunol. 160:1998;1285-1289.
67. Hohmann E.L., Oletta C.A., Loomis W.P., Miller S.I. Macrophage-inducible expression of a model antigen in Salmonella typhimurium enhances immunogenicity. Proc. Natl. Acad. Sci. USA. 92:1995;2904-2908.
68. Tramont E.C., Chung R., Berman S., Keren D., Kapfer C., Formal S.B. Safety and antigenicity of typhoid-Shigella sonnei vaccine (strain 5076- 1C). J. Infect. Dis. 149:1984;133-136.